Time-poor start-up founders need life science clusters to thrive
Mairi Dillion at Kadans
Trying to survive as a start-up can feel like an uphill battle. Finding investment, building partnerships, and reaching new audiences can be tricky on tight budgets and deadlines. And in the life sciences sector, this can prove even more challenging.
There are over 60,000 SMEs in human, health, and social work competing for survival, with a worrying half of new businesses failing within the first three years of operation. While the picture may seem bleak, the pharmaceutical sector is a pillar of the UK…
Neobe Therapeutics raises over $2m for synthetic biology enabled tumour microenvironment remodelling
Neobe Therapeutics, a pioneering synthetic biology startup at the forefront of immuno-oncology innovation, is thrilled to announce the successful closure of a $2.34m financing round. This significant financial milestone was achieved with the support of new investors Pioneer Group and 2048 Ventures, alongside existing backers Deep Science Ventures*, Cancer Research Horizons*, and Discovery Park Ventures. Additionally, the round received a non-dilutive grant award from UKRI’s Innovate UK Future Economy Investor Partnership Programme.
Neobe has built a synthetic biology platform to engineer safe…
Discovery Park to host two events to celebrate women in business and tackle challenges in women’s health.
Discovery Park, Kent’s thriving life science community, is marking International Women’s Day by supporting women in business and tackling gender bias in healthcare.
With female founded start-ups still struggling to access funding and a lack of women investors, there remains much to do to create an equitable environment for women in business. The femtech industry is a clear example of this gender bias, with male femtech founders consistently raising more capital despite over 70% of…
In a recent blog post – AMSBIO describe how life science research groups are using their BioPORTER®, Detachin™, and SoluLyse™ reagents to make groundbreaking advances in Parkinson’s research, hypersomnia studies and eco-friendly microbial ester production.
These novel reagents empower research by enhancing the efficiency, accuracy, and reproducibility of scientific investigations.
A collaborative effort led by Dr. Wenjing Wang at the University of Michigan and Dr. Xiaobo Mao of Johns Hopkins University School of Medicine has made exciting advances in the development of potential therapeutics…
Cambridge, UK 23 February 2024
We are pleased to announced the shortlist for the One Nucleus Awards 2024.
The One Nucleus Award categories are structured to reflect that breadth of R&D, investment, service provision and enabling support across the stakeholders. “Performance of the Year” being recognised in each category. The awards criteria recognise success between 1 December 2022 – 30 November 2023.
Best Performing Facilities Provider of the Year:
Babraham Research Campus
Bruntwood SciTech
Stevenage Bioscience Catalyst
Best Performing Investor of the Year:
Cambridge…
Cambridge, UK 23 February 2024 - We are thrilled to announce the winners of the One Nucleus Boston Bootcamp competition aimed at providing a focused ‘Getting US-ready’ experience.
Congratulations to:
The competition attracted a diverse range of entries from across the UK showcasing a breadth of innovation in R&D drug discovery and platform technologies enhancing the R&D efforts of others.
All applicants were extremely high quality and exemplars of the proposition quality and approach likely to attract interest from the MA ecosystem. Judges commented that the Presentation…
Aleta Biotherapeutics (Aleta), a clinical stage, immuno-oncology company with a CAR T-cell engager (CTE) platform that enables cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, today announce the first patient was dosed in a Phase 1/2 clinical trial. This trial is evaluating the Company’s first-in-class biologic CAR T-cell engager, ALETA-001, for the treatment of patients with B-cell malignancies who are relapsed/refractory to CD19-targeting CAR T-cell therapy.
Cancer Research UK’s Centre for Drug Development is sponsoring and conducting…
Biocair, an award-winning life science logistics expert, is pleased to announce the opening of its office in Bangalore, the company’s fourth office in India. Spread over 2500 square feet, the new office was inaugurated by Neha Naik, General Manager Biocair India, on February 13 alongside key customers and key partners. Biocair first established operations in the country in 2021 with its corporate office in Mumbai and other locations in New Delhi and Chennai.
Ms. Naik comments “The pharma business in India is worth approximately $50 billion and is expected to reach $100 billion by 2030 - we…
• Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases
• Targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year
OXFORD, UK and SALT LAKE CITY, US – 15 February 2024 – The pioneering precision medicine company, PrecisionLife, and leading US multi-specialty healthcare center, Metrodora Institute, are co-investing in a first-of-its-kind partnership to jumpstart the diagnosis and treatment options for a range of complex, chronic…